;PMID: 6421814
;source_file_1001.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..40] = [t:0..40]
;1)sentence:[e:46..105] = [t:46..105]
;2)sentence:[e:106..157] = [t:106..157]
;3)section:[e:161..192] = [t:161..192]
;4)sentence:[e:196..347] = [t:196..347]
;5)sentence:[e:348..693] = [t:348..693]
;6)sentence:[e:694..836] = [t:694..836]
;7)sentence:[e:838..972] = [t:838..972]
;8)sentence:[e:973..1047] = [t:973..1047]
;9)sentence:[e:1048..1155] = [t:1048..1155]
;10)sentence:[e:1156..1398] = [t:1156..1398]
;11)sentence:[e:1399..1683] = [t:1399..1683]
;12)sentence:[e:1684..1880] = [t:1684..1880]
;13)sentence:[e:1881..2125] = [t:1881..2125]
;14)sentence:[e:2126..2346] = [t:2126..2346]
;15)sentence:[e:2348..2617] = [t:2348..2617]
;16)section:[e:2621..2665] = [t:2621..2665]

;section 0 Span:0..40
;J Biol Chem. 1984 Feb 25;259(4):2675-82.
(SEC
  (FRAG (NNP:[0..1] J) (NNP:[2..6] Biol) (NNP:[7..11] Chem) (.:[11..12] .)
        (CD:[13..17] 1984) (NNP:[18..21] Feb) (CD:[22..24] 25)
        (CD:[24..29] ;259-LRB-) (CD:[29..31] 4-RRB-) (CD:[31..36] :2675)
        (::[36..37] -) (CD:[37..39] 82) (.:[39..40] .)))

;sentence 1 Span:46..105
;Isosafrole-induced cytochrome P2-450 in DBA/2N mouse liver.
;[46..56]:substance:"Isosafrole"
;[65..82]:cyp450:"cytochrome P2-450"
(SENT
  (NP-HLN
    (NP
      (ADJP (NN:[46..56] Isosafrole) (HYPH:[56..57] -) (VBN:[57..64] induced))
       (NN:[65..75] cytochrome) (NN:[76..82] P2-450))
    (PP-LOC (IN:[83..85] in)
      (NP (NN:[86..92] DBA/2N) (NN:[93..98] mouse) (NN:[99..104] liver)))
    (.:[104..105] .)))

;sentence 2 Span:106..157
;Characterization and  genetic control of induction.
(SENT
  (NP
    (NP
      (NP (NN:[106..122] Characterization))
      (CC:[123..126] and)
      (NP (JJ:[128..135] genetic) (NN:[136..143] control)))
    (PP (IN:[144..146] of)
      (NP (NN:[147..156] induction)))
    (.:[156..157] .)))

;section 3 Span:161..192
;Ohyama T, Nebert DW, Negishi M.
(SEC
  (FRAG (NNP:[161..167] Ohyama) (NNP:[168..169] T) (,:[169..170] ,)
        (NNP:[171..177] Nebert) (NNP:[178..180] DW) (,:[180..181] ,)
        (NNP:[182..189] Negishi) (NNP:[190..192] M.)))

;sentence 4 Span:196..347
;Mouse "cytochrome P2-450" is defined as that form of isosafrole-induced P-450
;in  DBA/2N liver most specifically correlated with isosafrole metabolism.
;[203..220]:cyp450:"cytochrome P2-450"
;[249..259]:substance:"isosafrole"
;[268..273]:cyp450:"P-450"
;[325..335]:substance:"isosafrole"
(SENT
  (S
    (NP-SBJ-1 (NN:[196..201] Mouse) (``:[202..203] ")
       (NN:[203..213] cytochrome) (NN:[214..220] P2-450)
      ('':[220..221] "))
    (VP (VBZ:[222..224] is)
      (VP (VBN:[225..232] defined)
        (NP-1 (-NONE-:[232..232] *))
        (PP-CLR (IN:[233..235] as)
          (NP
            (NP
              (NP (DT:[236..240] that) (NN:[241..245] form))
              (PP (IN:[246..248] of)
                (NP
                  (ADJP (NN:[249..259] isosafrole) (HYPH:[259..260] -)
                        (VBN:[260..267] induced))
                  (NN:[268..273] P-450)))
              (PP-LOC (IN:[274..276] in)
                (NP (NN:[278..284] DBA/2N) (NN:[285..290] liver))))
            (VP
              (ADVP (RBS:[291..295] most) (RB:[296..308] specifically))
              (VBN:[309..319] correlated)
              (NP (-NONE-:[319..319] *))
              (PP-CLR (IN:[320..324] with)
                (NP (NN:[325..335] isosafrole) (NN:[336..346] metabolism))))))))
    (.:[346..347] .)))

;sentence 5 Span:348..693
;Isosafrole  pretreatment does not induce aryl hydrocarbon hydroxylase
;activity ("cytochrome  P1-450") in C57BL/6N or DBA/2N mice, induces
;acetanilide 4-hydroxylase activity  ("cytochrome P3-450") more than 3-fold in
;C57BL/6N but not in DBA/2N mice, and  induces isosafrole metabolite formation
;more than 3-fold in both C57BL/6N and  DBA/2N mice.
;[348..358]:substance:"Isosafrole"
;[389..417]:cyp450:"aryl hydrocarbon hydroxylase"
;[429..447]:cyp450:"cytochrome  P1-450"
;[486..511]:cyp450:"acetanilide 4-hydroxylase"
;[524..541]:cyp450:"cytochrome P3-450"
;[554..560]:quantitative-value:"3-fold"
;[610..631]:substance:"isosafrole metabolite"
;[652..658]:quantitative-value:"3-fold"
(SENT
  (S
    (NP-SBJ (NN:[348..358] Isosafrole) (NN:[360..372] pretreatment))
    (VP
      (VP (VBZ:[373..377] does) (RB:[378..381] not)
        (VP (VB:[382..388] induce)
          (NP
             (NN:[389..393] aryl) (NN:[394..405] hydrocarbon)
             (NN:[406..417] hydroxylase)
            (NN:[418..426] activity)
            (PRN (-LRB-:[427..428] -LRB-)
              (NP (``:[428..429] ")
                 (NN:[429..439] cytochrome) (NN:[441..447] P1-450)
                ('':[447..448] "))
              (-RRB-:[448..449] -RRB-)))
          (PP-LOC (IN:[450..452] in)
            (NP
              (NP (NN:[453..461] C57BL/6N)
                (NML-4 (-NONE-:[461..461] *P*)))
              (CC:[462..464] or)
              (NP (NN:[465..471] DBA/2N)
                (NML-4 (NNS:[472..476] mice)))))))
      (,:[476..477] ,)
      (VP
        (VP (VBZ:[478..485] induces)
          (NP
            (NML (NN:[486..497] acetanilide) (NN:[498..511] 4-hydroxylase))
            (NN:[512..520] activity)
            (PRN (-LRB-:[522..523] -LRB-)
              (NP (``:[523..524] ")
                 (NN:[524..534] cytochrome) (NN:[535..541] P3-450)
                ('':[541..542] "))
              (-RRB-:[542..543] -RRB-)))
          (ADVP-EXT
            (QP (RBR:[544..548] more) (IN:[549..553] than)
               (CD:[554..555] 3) (HYPH:[555..556] -) (RB:[556..560] fold)))
          (PP-LOC=3 (IN:[561..563] in)
            (NP (NN:[564..572] C57BL/6N)
              (NML-2 (-NONE-:[572..572] *P*)))))
        (CC:[573..576] but)
        (VP (RB:[577..580] not)
          (PP-LOC=3 (IN:[581..583] in)
            (NP (NN:[584..590] DBA/2N)
              (NML-2 (NNS:[591..595] mice))))))
      (,:[595..596] ,) (CC:[597..600] and)
      (VP (VBZ:[602..609] induces)
        (NP
          (NP
             (NN:[610..620] isosafrole) (NN:[621..631] metabolite)
            (NN:[632..641] formation))
          (ADVP-EXT
            (QP (RBR:[642..646] more) (IN:[647..651] than)
               (CD:[652..653] 3) (HYPH:[653..654] -) (RB:[654..658] fold)))
          (PP-LOC (IN:[659..661] in)
            (NP (CC:[662..666] both)
              (NP (NN:[667..675] C57BL/6N)
                (NML-1 (-NONE-:[675..675] *P*)))
              (CC:[676..679] and)
              (NP (NN:[681..687] DBA/2N)
                (NML-1 (NNS:[688..692] mice))))))))
    (.:[692..693] .)))

;sentence 6 Span:694..836
;P2-450 was, therefore, purified from isosafrole-treated DBA/2N  liver
;microsomes having negligible amounts of contaminating P1-450 and P3-450.
;[694..700]:cyp450:"P2-450"
;[731..741]:substance:"isosafrole"
;[818..824]:cyp450:"P1-450"
;[829..835]:cyp450:"P3-450"
(SENT
  (S
    (NP-SBJ (NN:[694..700] P2-450))
    (VP (VBD:[701..704] was) (,:[704..705] ,)
      (ADVP (RB:[706..715] therefore))
      (,:[715..716] ,)
      (VP (VBN:[717..725] purified)
        (NP (-NONE-:[725..725] *))
        (PP (IN:[726..730] from)
          (NP
            (NP
              (ADJP (NN:[731..741] isosafrole) (HYPH:[741..742] -)
                    (VBN:[742..749] treated))
              (NN:[750..756] DBA/2N) (NN:[758..763] liver)
               (NNS:[764..774] microsomes))
            (VP (VBG:[775..781] having)
              (NP
                (NP (JJ:[782..792] negligible) (NNS:[793..800] amounts))
                (PP (IN:[801..803] of)
                  (NP
                    (NP
                      (ADJP-1 (VBG:[804..817] contaminating))
                      (NN:[818..824] P1-450))
                    (CC:[825..828] and)
                    (NP
                      (ADJP-1 (-NONE-:[828..828] *P*))
                      (NN:[829..835] P3-450))))))))))
    (.:[835..836] .)))

;sentence 7 Span:838..972
;The apparent molecular weight of P2-450 is 55,000, and the protein appears 
;homogeneous on sodium dodecyl sulfate-polyacrylamide gels.
;[871..877]:cyp450:"P2-450"
;[881..887]:quantitative-value:"55,000"
;[897..904]:cyp450:"protein"
;[929..966]:substance:"sodium dodecyl sulfate-polyacrylamide"
(SENT
  (S
    (S
      (NP-SBJ
        (NP (DT:[838..841] The) (JJ:[842..850] apparent)
            (JJ:[851..860] molecular) (NN:[861..867] weight))
        (PP (IN:[868..870] of)
          (NP (NN:[871..877] P2-450))))
      (VP (VBZ:[878..880] is)
        (NP-PRD (CD:[881..887] 55,000))))
    (,:[887..888] ,) (CC:[889..892] and)
    (S
      (NP-SBJ
        (NP-SBJ-1 (DT:[893..896] the) (NN:[897..904] protein))
        (VP (VBZ:[905..912] appears)
          (S
            (NP-SBJ-1 (-NONE-:[912..912] *))
            (ADJP-PRD (JJ:[914..925] homogeneous))
            (PP (IN:[926..928] on)
              (NP
                (NML
                  (NML (NN:[929..935] sodium) (NN:[936..943] dodecyl)
                       (NN:[944..951] sulfate))
                  (HYPH:[951..952] -) (NN:[952..966] polyacrylamide))
                (NNS:[967..971] gels)))))))
    (.:[971..972] .)))

;sentence 8 Span:973..1047
;The Soret peak of the  reduced purified cytochrome X CO complex is 448 nm.
;[1013..1023]:cyp450:"cytochrome"
;[1026..1036]:substance:"CO complex"
;[1040..1043]:quantitative-value:"448"
;[1044..1046]:quantitative-units:"nm"
(SENT
  (S
    (NP-SBJ
      (NP (DT:[973..976] The) (NNP:[977..982] Soret) (NN:[983..987] peak))
      (PP (IN:[988..990] of)
        (NP (DT:[991..994] the) (VBN:[996..1003] reduced)
            (VBN:[1004..1012] purified)
          (NML
            (NML (NN:[1013..1023] cytochrome))
            (PP (SYM:[1024..1025] X)
              (NP (NN:[1026..1028] CO))))
          (NN:[1029..1036] complex))))
    (VP (VBZ:[1037..1039] is)
      (NP-PRD (CD:[1040..1043] 448) (NN:[1044..1046] nm)))
    (.:[1046..1047] .)))

;sentence 9 Span:1048..1155
;Purified P2-450,  reconstituted in vitro, metabolizes acetanilide poorly and
;benzo[a]pyrene hardly  at all.
;[1057..1063]:cyp450:"P2-450"
;[1102..1113]:substance:"acetanilide"
;[1125..1139]:substance:"benzo[a]pyrene"
(SENT
  (S
    (NP-SBJ
      (NP (VBN:[1048..1056] Purified) (NN:[1057..1063] P2-450))
      (,:[1063..1064] ,)
      (VP (VBN:[1066..1079] reconstituted)
        (NP (-NONE-:[1079..1079] *))
        (ADVP (FW:[1080..1082] in) (FW:[1083..1088] vitro))))
    (,:[1088..1089] ,)
    (VP
      (VP (VBZ:[1090..1101] metabolizes)
        (NP=1 (NN:[1102..1113] acetanilide))
        (ADVP=2 (RB:[1114..1120] poorly)))
      (CC:[1121..1124] and)
      (VP
        (NP=1 (NN:[1125..1139] benzo-LSB-a-RSB-pyrene))
        (ADVP=2 (RB:[1140..1146] hardly)
          (ADVP (IN:[1148..1150] at) (DT:[1151..1154] all)))))
    (.:[1154..1155] .)))

;sentence 10 Span:1156..1398
;Anti-(P2-450) inhibits (90 to 100%) liver microsomal isosafrole  metabolite
;formation, yet has no effect on aryl hydrocarbon hydroxylase,  acetanilide
;4-hydroxylase, biphenyl 2- or 4-hydroxylase, or 7-ethoxycoumarin 
;O-de-ethylase activities.
;[1156..1169]:substance:"Anti-(P2-450)"
;[1180..1190]:quantitative-value:"90 to 100%"
;[1209..1231]:substance:"isosafrole  metabolite"
;[1264..1292]:cyp450:"aryl hydrocarbon hydroxylase"
;[1295..1320]:cyp450:"acetanilide 4-hydroxylase"
;[1322..1332]...[1339..1350]:substance:"biphenyl 2"..."hydroxylase"
;[1322..1330]...[1337..1350]:substance:"biphenyl"..."4-hydroxylase"
;[1355..1386]:substance:"7-ethoxycoumarin  O-de-ethylase"
(SENT
  (S
    (NP-SBJ (AFX:[1156..1160] Anti) (HYPH:[1160..1161] -)
            (-LRB-:[1161..1162] -LRB-) (NN:[1162..1168] P2-450)
            (-RRB-:[1168..1169] -RRB-))
    (VP
      (VP (VBZ:[1170..1178] inhibits)
        (PRN (-LRB-:[1179..1180] -LRB-)
          (NP
            (QP (CD:[1180..1182] 90) (TO:[1183..1185] to) (CD:[1186..1189] 100))
            (NN:[1189..1190] %))
          (-RRB-:[1190..1191] -RRB-))
        (NP
          (NML (NN:[1192..1197] liver) (JJ:[1198..1208] microsomal)
             (NN:[1209..1219] isosafrole) (NN:[1221..1231] metabolite))
          (NN:[1232..1241] formation)))
      (,:[1241..1242] ,) (CC:[1243..1246] yet)
      (VP (VBZ:[1247..1250] has)
        (NP
          (NP (DT:[1251..1253] no) (NN:[1254..1260] effect))
          (PP (IN:[1261..1263] on)
            (NP
              (NP
                (NML (NN:[1264..1268] aryl) (NN:[1269..1280] hydrocarbon)
                     (NN:[1281..1292] hydroxylase))
                (NML-3 (-NONE-:[1292..1292] *P*)))
              (,:[1292..1293] ,)
              (NP
                (NML (NN:[1295..1306] acetanilide)
                     (NN:[1307..1320] 4-hydroxylase))
                (NML-3 (-NONE-:[1320..1320] *P*)))
              (,:[1320..1321] ,)
              (NP
                (NP
                  (NML
                    (NML-2 (NN:[1322..1330] biphenyl))
                    (CD:[1331..1332] 2) (HYPH:[1332..1333] -)
                    (NML-1 (-NONE-:[1333..1333] *P*)))
                  (NML-3 (-NONE-:[1333..1333] *P*)))
                (CC:[1334..1336] or)
                (NP
                  (NML
                    (NML-2 (-NONE-:[1336..1336] *P*))
                    (CD:[1337..1338] 4) (HYPH:[1338..1339] -)
                    (NML-1 (NN:[1339..1350] hydroxylase)))
                  (NML-3 (-NONE-:[1350..1350] *P*))))
              (,:[1350..1351] ,) (CC:[1352..1354] or)
              (NP
                (NML (NN:[1355..1371] 7-ethoxycoumarin)
                     (NN:[1373..1386] O-de-ethylase))
                (NML-3 (NNS:[1387..1397] activities))))))))
    (.:[1397..1398] .)))

;sentence 11 Span:1399..1683
;3-Methylcholanthrene induces  anti-(P2-450)-precipitable protein about
;12-fold in C57BL/6N and 2-fold in  DBA/2N liver;
;2,3,7,8-tetrachlorodibenzo-p-dioxin (10 micrograms/kg), about  12-fold in
;both C57BL/6N and DBA/2N liver; isosafrole, more than 3-fold in both 
;C57BL/6N and DBA/2N.
;[1399..1419]:substance:"3-Methylcholanthrene"
;[1429..1463]:substance:"anti-(P2-450)-precipitable protein"
;[1470..1477]:quantitative-value:"12-fold"
;[1494..1500]:quantitative-value:"2-fold"
;[1519..1554]:substance:"2,3,7,8-tetrachlorodibenzo-p-dioxin"
;[1556..1558]:quantitative-value:"10"
;[1559..1572]:quantitative-units:"micrograms/kg"
;[1582..1589]:quantitative-value:"12-fold"
;[1625..1635]:substance:"isosafrole"
;[1647..1653]:quantitative-value:"3-fold"
(SENT
  (S
    (S
      (NP-SBJ=5 (NN:[1399..1419] 3-Methylcholanthrene))
      (VP
        (VP (VBZ:[1420..1427] induces)
          (NP
            (ADJP
              (ADJP (AFX:[1429..1433] anti) (HYPH:[1433..1434] -)
                    (-LRB-:[1434..1435] -LRB-) (NN:[1435..1441] P2-450)
                    (-RRB-:[1441..1442] -RRB-))
              (HYPH:[1442..1443] -) (JJ:[1443..1455] precipitable))
            (NN:[1456..1463] protein))
          (ADVP-EXT=2
            (QP (RB:[1464..1469] about)
               (CD:[1470..1472] 12) (HYPH:[1472..1473] -) (RB:[1473..1477] fold)))
          (PP-LOC=3 (IN:[1478..1480] in)
            (NP (NN:[1481..1489] C57BL/6N)
              (NML-1 (-NONE-:[1489..1489] *P*)))))
        (CC:[1490..1493] and)
        (VP
          (ADVP-EXT=2
            (QP (CD:[1494..1495] 2) (HYPH:[1495..1496] -) (RB:[1496..1500] fold)))
          (PP-LOC=3 (IN:[1501..1503] in)
            (NP (NN:[1505..1511] DBA/2N)
              (NML-1 (NN:[1512..1517] liver)))))))
    (::[1517..1518] ;)
    (S
      (NP-SBJ=5 (NN:[1519..1554] 2,3,7,8-tetrachlorodibenzo-p-dioxin)
        (PRN (-LRB-:[1555..1556] -LRB-)
          (NP
            (NP (CD:[1556..1558] 10) (NN:[1559..1569] micrograms))
            (PP (SYM:[1569..1570] /)
              (NP (NN:[1570..1572] kg))))
          (-RRB-:[1572..1573] -RRB-)))
      (,:[1573..1574] ,)
      (ADVP-EXT=2
        (QP (RB:[1575..1580] about)
           (CD:[1582..1584] 12) (HYPH:[1584..1585] -) (RB:[1585..1589] fold)))
      (PP-LOC=3 (IN:[1590..1592] in)
        (NP (CC:[1593..1597] both)
          (NP (NN:[1598..1606] C57BL/6N)
            (NML-4 (-NONE-:[1606..1606] *P*)))
          (CC:[1607..1610] and)
          (NP (NN:[1611..1617] DBA/2N)
            (NML-4 (NN:[1618..1623] liver))))))
    (::[1623..1624] ;)
    (S
      (NP-SBJ=5 (NN:[1625..1635] isosafrole))
      (,:[1635..1636] ,)
      (ADVP-EXT=2
        (QP (JJR:[1637..1641] more) (IN:[1642..1646] than)
           (CD:[1647..1648] 3) (HYPH:[1648..1649] -) (RB:[1649..1653] fold)))
      (PP-LOC=3 (IN:[1654..1656] in)
        (NP (CC:[1657..1661] both) (NN:[1663..1671] C57BL/6N)
            (CC:[1672..1675] and) (NN:[1676..1682] DBA/2N))))
    (.:[1682..1683] .)))

;sentence 12 Span:1684..1880
;Benzo[a]anthracene at maximal doses induces  anti-(P2-450)-precipitable
;protein in C57BL/6N liver no more than 2-fold, yet is  known to be a highly
;potent inducer of P1-450 mRNA in C57BL/6N liver.
;[1684..1702]:substance:"Benzo[a]anthracene"
;[1729..1763]:substance:"anti-(P2-450)-precipitable protein"
;[1795..1801]:quantitative-value:"2-fold"
;[1839..1846]:substance:"inducer"
;[1850..1861]:substance:"P1-450 mRNA"
(SENT
  (S
    (NP-SBJ-1
      (NP (NN:[1684..1702] Benzo-LSB-a-RSB-anthracene))
      (PP (IN:[1703..1705] at)
        (NP (JJ:[1706..1713] maximal) (NNS:[1714..1719] doses))))
    (VP
      (VP (VBZ:[1720..1727] induces)
        (NP
          (ADJP
            (ADJP (AFX:[1729..1733] anti) (HYPH:[1733..1734] -)
                  (-LRB-:[1734..1735] -LRB-) (NN:[1735..1741] P2-450)
                  (-RRB-:[1741..1742] -RRB-))
            (HYPH:[1742..1743] -) (JJ:[1743..1755] precipitable))
          (NN:[1756..1763] protein))
        (PP-LOC (IN:[1764..1766] in)
          (NP (NN:[1767..1775] C57BL/6N) (NN:[1776..1781] liver)))
        (ADVP-EXT
          (QP (RB:[1782..1784] no) (RBR:[1785..1789] more)
              (IN:[1790..1794] than)
             (CD:[1795..1796] 2) (HYPH:[1796..1797] -) (RB:[1797..1801] fold))))
      (,:[1801..1802] ,) (CC:[1803..1806] yet)
      (VP (VBZ:[1807..1809] is)
        (VP (VBN:[1811..1816] known)
          (S
            (NP-SBJ-1 (-NONE-:[1816..1816] *))
            (VP (TO:[1817..1819] to)
              (VP (VB:[1820..1822] be)
                (NP-PRD
                  (NP (DT:[1823..1824] a)
                    (ADJP (RB:[1825..1831] highly) (JJ:[1832..1838] potent))
                    (NN:[1839..1846] inducer))
                  (PP (IN:[1847..1849] of)
                    (NP (NN:[1850..1856] P1-450) (NN:[1857..1861] mRNA))))
                (PP-LOC (IN:[1862..1864] in)
                  (NP (NN:[1865..1873] C57BL/6N) (NN:[1874..1879] liver)))))))))
    (.:[1879..1880] .)))

;sentence 13 Span:1881..2125
;The  sensitivity of the P2-450 induction process to isosafrole is inherited
;as an  autosomal additive trait; studies of offspring from the
;C57BL/6N(DBA/N)F1 X  DBA/2N backcross confirm involvement of the Ah locus or
;s closely segregating  gene.
;[1905..1911]:cyp450:"P2-450"
;[1933..1943]:substance:"isosafrole"
(SENT
  (S
    (S
      (NP-SBJ-1
        (NP (DT:[1881..1884] The) (NN:[1886..1897] sensitivity))
        (PP (IN:[1898..1900] of)
          (NP (DT:[1901..1904] the) (NN:[1905..1911] P2-450)
              (NN:[1912..1921] induction) (NN:[1922..1929] process)))
        (PP (TO:[1930..1932] to)
          (NP (NN:[1933..1943] isosafrole))))
      (VP (VBZ:[1944..1946] is)
        (VP (VBN:[1947..1956] inherited)
          (NP-1 (-NONE-:[1956..1956] *))
          (PP (IN:[1957..1959] as)
            (NP (DT:[1960..1962] an) (JJ:[1964..1973] autosomal)
                (JJ:[1974..1982] additive) (NN:[1983..1988] trait))))))
    (::[1988..1989] ;)
    (S
      (NP-SBJ
        (NP (NNS:[1990..1997] studies))
        (PP (IN:[1998..2000] of)
          (NP
            (NP (NN:[2001..2010] offspring))
            (PP (IN:[2011..2015] from)
              (NP (DT:[2016..2019] the)
                (NML
                  (NML (NN:[2020..2037] C57BL/6N-LRB-DBA/N-RRB-F1))
                  (PP (SYM:[2038..2039] X)
                    (NP (NN:[2041..2047] DBA/2N))))
                (NN:[2048..2057] backcross))))))
      (VP (VBP:[2058..2065] confirm)
        (NP
          (NP (NN:[2066..2077] involvement))
          (PP (IN:[2078..2080] of)
            (NP
              (NP (DT:[2081..2084] the) (NN:[2085..2087] Ah)
                  (NN:[2088..2093] locus))
              (CC:[2094..2096] or)
              (NP (NN:[2097..2098] s)
                (ADJP (RB:[2099..2106] closely) (VBG:[2107..2118] segregating))
                (NN:[2120..2124] gene)))))))
    (.:[2124..2125] .)))

;sentence 14 Span:2126..2346
;In contrast, among crosses between C57BL/6N and DBA/2N, sensitivity of the 
;P1-450 and P3-450 induction process to 3-methylcholanthrene or 
;2,3,7,8-tetrachlorodibenzo-p-dioxin is inherited as an autosomal dominant
;trait.
;[2202..2208]:cyp450:"P1-450"
;[2213..2219]:cyp450:"P3-450"
;[2241..2261]:substance:"3-methylcholanthrene"
;[2266..2301]:substance:"2,3,7,8-tetrachlorodibenzo-p-dioxin"
(SENT
  (S
    (PP (IN:[2126..2128] In)
      (NP (NN:[2129..2137] contrast)))
    (,:[2137..2138] ,)
    (PP (IN:[2139..2144] among)
      (NP
        (NP (NNS:[2145..2152] crosses))
        (PP (IN:[2153..2160] between)
          (NP (NN:[2161..2169] C57BL/6N) (CC:[2170..2173] and)
              (NN:[2174..2180] DBA/2N)))))
    (,:[2180..2181] ,)
    (NP-SBJ-1
      (NP (NN:[2182..2193] sensitivity))
      (PP (IN:[2194..2196] of)
        (NP (DT:[2197..2200] the)
          (NML (NN:[2202..2208] P1-450) (CC:[2209..2212] and)
               (NN:[2213..2219] P3-450))
          (NN:[2220..2229] induction) (NN:[2230..2237] process)))
      (PP (TO:[2238..2240] to)
        (NP (NN:[2241..2261] 3-methylcholanthrene) (CC:[2262..2264] or)
            (NN:[2266..2301] 2,3,7,8-tetrachlorodibenzo-p-dioxin))))
    (VP (VBZ:[2302..2304] is)
      (VP (VBN:[2305..2314] inherited)
        (NP-1 (-NONE-:[2314..2314] *))
        (PP (IN:[2315..2317] as)
          (NP (DT:[2318..2320] an) (JJ:[2321..2330] autosomal)
              (JJ:[2331..2339] dominant) (NN:[2340..2345] trait)))))
    (.:[2345..2346] .)))

;sentence 15 Span:2348..2617
;These data suggest that, although P1-450, P2-450, and P3-450 proteins are 
;controlled by the Ah locus, either a P-450 protein polymorphism exists
;between  C57BL/6N and DBA/2N mice or subtle differences may exist in the
;interaction of  various inducers with Ah receptor.
;[2382..2388]...[2409..2417]:cyp450:"P1-450"..."proteins"
;[2390..2396]...[2409..2417]:cyp450:"P2-450"..."proteins"
;[2402..2417]:cyp450:"P3-450 proteins"
;[2460..2473]:cyp450:"P-450 protein"
;[2605..2616]:substance:"Ah receptor"
(SENT
  (S
    (NP-SBJ (DT:[2348..2353] These) (NNS:[2354..2358] data))
    (VP (VBP:[2359..2366] suggest)
      (SBAR (IN:[2367..2371] that) (,:[2371..2372] ,)
        (S
          (SBAR-ADV (IN:[2373..2381] although)
            (S
              (NP-SBJ-2
                (NP (NN:[2382..2388] P1-450)
                  (NML-3 (-NONE-:[2388..2388] *P*)))
                (,:[2388..2389] ,)
                (NP (NN:[2390..2396] P2-450)
                  (NML-3 (-NONE-:[2396..2396] *P*)))
                (,:[2396..2397] ,) (CC:[2398..2401] and)
                (NP (NN:[2402..2408] P3-450)
                  (NML-3 (NNS:[2409..2417] proteins))))
              (VP (VBP:[2418..2421] are)
                (VP (VBN:[2423..2433] controlled)
                  (NP-2 (-NONE-:[2433..2433] *))
                  (PP (IN:[2434..2436] by)
                    (NP-LGS (DT:[2437..2440] the) (NN:[2441..2443] Ah)
                            (NN:[2444..2449] locus)))))))
          (,:[2449..2450] ,) (CC:[2451..2457] either)
          (S
            (NP-SBJ (DT:[2458..2459] a)
               (NN:[2460..2465] P-450) (NN:[2466..2473] protein)
              (NN:[2474..2486] polymorphism))
            (VP (VBZ:[2487..2493] exists)
              (PP (IN:[2494..2501] between)
                (NP
                  (NP (NN:[2503..2511] C57BL/6N)
                    (NML-1 (-NONE-:[2511..2511] *P*)))
                  (CC:[2512..2515] and)
                  (NP (NN:[2516..2522] DBA/2N)
                    (NML-1 (NNS:[2523..2527] mice)))))))
          (CC:[2528..2530] or)
          (S
            (NP-SBJ (JJ:[2531..2537] subtle) (NNS:[2538..2549] differences))
            (VP (RB:[2550..2553] may)
              (VP (VB:[2554..2559] exist)
                (PP (IN:[2560..2562] in)
                  (NP
                    (NP (DT:[2563..2566] the) (NN:[2567..2578] interaction))
                    (PP (IN:[2579..2581] of)
                      (NP (JJ:[2583..2590] various) (NNS:[2591..2599] inducers)))
                    (PP (IN:[2600..2604] with)
                      (NP (NN:[2605..2607] Ah) (NN:[2608..2616] receptor)))))))))))
    (.:[2616..2617] .)))

;section 16 Span:2621..2665
;PMID: 6421814 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[2621..2625] PMID) (::[2625..2626] :) (CD:[2627..2634] 6421814)
        (NN:[2635..2636] -LSB-) (NNP:[2636..2642] PubMed) (::[2643..2644] -)
        (NN:[2645..2652] indexed) (IN:[2653..2656] for)
        (NNP:[2657..2665] MEDLINE-RSB-)))